Literature DB >> 10424204

Candida glabrata Fungemia. Clinical features of 139 patients.

T Gumbo1, C M Isada, G Hall, M T Karafa, S M Gordon.   

Abstract

Candida species are now the fourth leading cause of nosocomial bloodstream infection in hospitalized patients, and non-Candida albicans species now surpass Candida albicans. The clinical features of the most common non-Candida albicans species, Candida (Torulopsis) glabrata, have not been well studied. We retrospectively reviewed the clinical features of 139 patients with C. glabrata blood-stream infection over a period of 7 years. The mean age of patients was 62 years, and the most common admitting diagnoses were malignancy (28%) and coronary artery disease (18%). The most common identified portals of entry were abdominal (22%) and intravascular catheters (16%). At the time of fungemia, 63% of patients had fever, 45% had change in mental status, and 30% were in septic shock. Three of 50 patients examined by an ophthalmologist had chorioretinitis. The overall hospital mortality was 49%. Factors associated with increased mortality in a regression model were prior abdominal surgery (odds ratio [OR] = 2.8; 95% confidence interval [CI] = 1.2-6.3, p = 0.01), and an elevated creatinine (OR = 2.2; 95% CI = 1.0-4.7, p = 0.05). When early deaths (< or = 72 hours) were censored, amphotericin B treatment and total dose were associated with reduced mortality (OR = 0.2; 95% CI = 0.1-0.4, p < 0.001). Nosocomial C. glabrata fungemia is not just a disease of debilitated and neutropenic patients, but affects a wide variety of patients and is associated with a high mortality.

Entities:  

Mesh:

Year:  1999        PMID: 10424204     DOI: 10.1097/00005792-199907000-00002

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  21 in total

1.  Management of Infections Caused by Candida glabrata.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

Review 2.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 3.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  An expanding stage for commensal microbes in host immune regulation.

Authors:  Yan Shi; Libing Mu
Journal:  Cell Mol Immunol       Date:  2017-01-09       Impact factor: 11.530

5.  Use of amplified fragment length polymorphism analysis to identify medically important Candida spp., including C. dubliniensis.

Authors:  A Borst; B Theelen; E Reinders; T Boekhout; A C Fluit; P H M Savelkoul
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

6.  Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Robert W Kulawy; Christine Fregeau; Vasha Hsu; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

7.  Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).

Authors:  Amar Safdar; Vishnu Chaturvedi; Brian S Koll; Davise H Larone; David S Perlin; Donald Armstrong
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

10.  Multilocus sequence typing of Candida glabrata reveals geographically enriched clades.

Authors:  Andrew R Dodgson; Claude Pujol; David W Denning; David R Soll; Andrew J Fox
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.